ArticleClinical and diagnostic laboratory immunology2003
Specificity and diversity of antibodies to Mycobacterium tuberculosis arabinomannan.
Article in Clinical and diagnostic laboratory immunology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Determination of variable region sequences from hybridoma immunoglobulins that target Mycobacterium tuberculosis virulence factors.PloS one · 2021Article
- Lipoarabinomannan in Active and Passive Protection Against Tuberculosis.Frontiers in immunology · 2019Review
- Enhanced control of Mycobacterium tuberculosis extrapulmonary dissemination in mice by an arabinomannan-protein conjugate vaccine.PLoS pathogens · 2017Article
- Association of Human Antibodies to Arabinomannan With Enhanced Mycobacterial Opsonophagocytosis and Intracellular Growth Reduction.The Journal of infectious diseases · 2016Article
- Enhanced virulence of Histoplasma capsulatum through transfer and surface incorporation of glycans from Cryptococcus neoformans during co-infection.Scientific reports · 2016Article
- Evaluation of Anti-TBGL Antibody in the Diagnosis of Tuberculosis Patients in China.Journal of immunology research · 2015Article
- Antibody-mediated immunity against tuberculosis: implications for vaccine development.Cell host & microbe · 2013Review
- Comparative evaluation of profiles of antibodies to mycobacterial capsular polysaccharides in tuberculosis patients and controls stratified by HIV status.Clinical and vaccine immunology : CVI · 2012Article
- Monoclonal antibodies to Mycobacterium tuberculosis CDC 1551 reveal subcellular localization of MPT51.Tuberculosis (Edinburgh, Scotland) · 2007Article
- Polysaccharide structural variability in mycobacteria: identification and characterization of phosphorylated mannan and arabinomannan.Glycoconjugate journal · 2007Article
- Utility of pentose colorimetric assay for the purification of potato lectin, an arabinose-rich glycoprotein.Glycoconjugate journal · 2006Article
- A monoclonal antibody to Bacillus anthracis protective antigen defines a neutralizing epitope in domain 1.Infection and immunity · 2006Article
- Peptide mimotopes of Mycobacterium tuberculosis carbohydrate immunodeterminants.The Biochemical journal · 2005Article
- A mycobacterial lipoarabinomannan specific monoclonal antibody and its F(ab') fragment prolong survival of mice infected with Mycobacterium tuberculosis.Clinical and experimental immunology · 2004Article
- Antigenic evidence of prevalence and diversity of Mycobacterium tuberculosis arabinomannan.Journal of clinical microbiology · 2004Article
- Cryptococcus neoformans CAP59 (or Cap59p) is involved in the extracellular trafficking of capsular glucuronoxylomannan.Eukaryotic cell · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
Arabinomannan (AM) is a polysaccharide antigen of the mycobacterial capsule. However, it is uncertain whether AM constitutes an immunologically distinct fraction of Mycobacterium tuberculosis. In this study, we analyzed the repertoire and specificity of antibodies to AM by using AM-binding murine monoclonal antibodies (MAbs) and human serum samples. Murine MAbs were found to be diverse in their specificity to AM and cross-reactivity with other arabinose-containing mycobacterial polysaccharides, with MAb 9d8 binding exclusively to AM. Human antibodies to AM were detected in serum samples from patients with pulmonary tuberculosis (TB), as well as in those from healthy, purified protein derivative-negative controls, with significantly higher titers among patients. The binding of human antibodies to AM was inhibited by MAb 9d8 in three patients with TB but not in controls. MAb 5c11, which recognizes other mycobacterial arabinose-containing carbohydrates in addition to AM, inhibited the binding of serum samples from 75% of patients and 76% of controls. Analysis of human antibodies with murine MAbs to human V(H) determinants demonstrated diversity among antibodies to AM with qualitative and quantitative differences compared with antibodies to lipoarabinomannan. In summary, our study suggests that antibodies to AM are diverse and heterogeneous with respect to antigen recognition and V(H) determinant expression, with human serum samples containing different subsets of antibodies to AM with the specificities of AM-binding murine MAbs. One MAb and a subset of human antibodies bind AM specifically, suggesting that this polysaccharide is antigenically distinct and is expressed in human infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.